Rapa lengthens mouse lifespan in multiple studies.
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Rapa lengthens mouse lifespan in multiple studies.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
Rapa lengthens mouse lifespan in multiple studies.
Rapa lengthens mouse lifespan in multiple studies.
In 2009 a study in older mice showed that dosing rapamy increased lifespan for females 14% and males 9% When they repeated the study in younger mice they showed that rapamy further increased longevity Now when they combined rapamy with other drugs such as a carbos they showed even further longevity benefits In females it was 28% in males it was 34%
Rapamycin extends lifespan in mice - https://t.co/lE1qLwubLs
what was interesting in the mice as they started late in life they started at 600 days which is that's about 60 years old yeah that's that's like starting is with this room that was really late in life for the my yeah yeah I was Wow made it that much more impressed
we did do a lower dose for three months as well and there we saw increases in lifespan in both males and females roughly the same magnitude so it was that dose was nine times higher than what the ITP tested
so it was that dose was nine times higher than what the ITP tested well
in 2009 this mouse study comes out it was the first of what would become a series of very interesting highly reproduced itps funded by nih that sort of did something we didn't typically see which is consistently across multiple labs and across different strains show the same result
we had in 2012 at least three or four years of very good evidence that rapamycin could be beneficial to extend lifespan through the itps so the interventions testing programs run through nih there had been several indications either directly through administration of rapamycin or indirectly through genetic inhibition of mtor that you could extend the life of yeast worms flies and mice
and the rapa solo which joan is pretty impressive as well was i believe 16 and 9 by gender right
yes then that was the first drug that gave a very strong signal in both males and females and it's still the only drug that we've tested so far which gives a very strong signal in females
the median extension which we've already said not as interesting that's just saying what's the age at which half the animals have died and the males went up 20 percent and the females that went up 13
the ones i've have ingrained in my head and maybe i hope i have them right is the the p90 life lifespan extension which in males was nine percent in females was 14
the maximum extension in males went from 9 to 11 percent and in females it went from 14 to 16
the ITP was the first study that really put rapid mice on the map in 2009 that was the study that's fortuitously demonstrated that even when ravamycin was given very very late in life it was given to 60 month old mice it still afforded them a 15 lifespan extension
yeah well Rapa uh in in our 2009 paper had a really big effect uh at we picked a dose um that seemed like it it might work and it did it's not the optimal dose it's less than the optimal dose but it's the dose we chose both males and females had a significant lifespan extension
in both sexes starting as late as 20 months of age does not diminish the um uh ability of the drug to extend lifespan
rapy um in that first paper was also the first drug I believe where anyone had showed we we found that it works quite well even if you start in really old mice some of the mice that were exposed in that paper didn't start until 20 months of age where the median survival is about 24 for males and 26 for females
yeah well Rapa uh in in our 2009 paper had a really big effect the dose we chose both males and females had a significant lifespan extension
uh in in our 2009 paper had a really big effect uh at we picked a dose that seemed like it it might work and it did it's not that optimal dose it's less than the optimal dose but the dose we chose both males and females had a significant lifespan extension to put this into perspective these drugs are giving at the M middle dose 15 to 20% increase in median lifespan
when Randy finally with his colleagues figured out how to make the protected version the encapsulated version of Rapa mice and we actually used it twice the same batches some of it went to the mice that were already 20 months of age so we wouldn't have to throw them out and then we executed we gave the rest to the young mice that had been produced in uh the following year expecting that the old mice it would fail the young mice it might work and as you know it worked well in both ages
fast forward to 2009 and um a very wellone study is published as part of the interventions testing program that looks at the use of Ramy in a very well documented strain of mice that are far more representative of what happens in biology than the typical strain of mice that are used in a clinical research setting you know the rest is history basically that study showed more convincingly than any other study in the ITP history that Rapa extended life in male mice in female mice and most importantly when initiated very late in life a period of time in which No Other Drug had ever been able to extend life
the ITP very consistently um even you know whether you talk about its home run drugs like rapy um and Other Drugs like recently 17 Alpha estradiol um they they disproportionately favor the male mice over the female mice
And without exception, every single ITP study of rapamy, whether they started in old mice or young mice, RAPA alone, RAPA with another drug, it just doesn't matter. It always worked.
Rapamycin was the drug that emerged as being robust and reproducible at all three sites where these experiments were conducted in mice.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.